Global metastatic bone disease market expected to generate revenue of around USD 20,992.7 million by end of 2024, growing at a CAGR of around 7.89% between 2018 and 2024. Metastatic bone disease is a condition that arises from cancer spread to the bones at an advanced stage. This condition causes bone degeneration, fractures, severe pain, anemia, and others.
The report covers forecast and analysis for the metastatic bone disease market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the metastatic bone disease market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the metastatic bone disease market on a global level.
In order to give the users of this report a comprehensive view of the metastatic bone disease market, we have included competitive landscape and analysis of Porter’s Five Forces model in the market. The study encompasses a market attractiveness analysis, wherein treatment, origin, end use, and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments in the market, including acquisitions & mergers, new treatment launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved on the market on the global and regional basis.
The study provides a decisive view on the metastatic bone disease market by segmenting the market based on test type, drug type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market are estimated from 2018 to 2024.
Based on treatment, the metastatic bone disease market is segmented as medication, radiation therapy, surgical intervention, and tumor ablation therapy. Based on origin, the metastatic bone disease market is segmented as breast, lung, thyroid, kidney, prostate, and others. Based on the end user, the metastatic bone disease market is segmented as hospitals, specialty clinics, and ambulatory surgical centers
Increased prevalence of cancer is one of the major driving factors of metastatic bone disease market. High investment on the drug discovery and development which is further supported the FDA approval of various drugs for the treatment of metastatic bone disease market. A long interval of time is required for the developments of drugs are the factors that influence the market growth during the forecast period.
The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries, including the U.S., Germany, France, UK, China, Japan, India, and Brazil. This segment includes the demand for metastatic bone disease market based on individual segment and treatment in all the regions and countries.
The report also includes detailed profiles of end players such as Merck & Co., Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Amgen, Inc., Novartis AG, Bayer AG, BTG plc, Fresenius Kabi AG, Medtronic, Boston Scientific Corporation, and others.
This report segments the global Metastatic Bone Disease Market as follows:
Global Metastatic Bone Disease Market: Treatment Analysis
Global Metastatic Bone Disease Market: Origin Analysis
Global Metastatic Bone Disease Market: End User Analysis
Global Metastatic Bone Disease Market: Regional Analysis
As there are various developments being made in the research field there is also a constant increase in the number of various diseases such as cancer, autoimmune diseases, and others. Bone metastasis is an advanced stage of cancer which spread to other parts of the body which mainly includes lung, liver, and bones. This will add up the treatment cost and the chances of getting cured also reduce. Bone metastasis leads to the degeneration of bones and can cause various fractures which cannot be treated. This can cause severe pain, anemia, spinal cord compression, hypercalcemia, and various other conditions. This can be diagnosed by CT scan and treatment includes prevention and treatment of fractures, pain control, local tumor control, and maintenance of patient function. Treatment options are chosen on various factors which include performance status, impact on quality of life, life expectancy, and the overall status of the clinical disease.
There is a constant increase in the prevalence of cancer over the period of time and reimbursement policies are the major factors driving the growth of metastatic bone disease market over the forecast period. Cancer begins in an organ and then spreads to bones and as per the National Cancer Institute in 2018 an estimated 1,735,350 new cases of cancer will be diagnosed in the United States. The companies are also focused towards developing new and effective treatments for the cancer patients which will further help in providing a better life.
The companies are constantly investing in research and development and there are various new drugs being developed by the companies and few are under development. This may further fuel the metastatic bone disease market over the forecast period. Moreover, there are various drugs approved by FDA for treatment and various organizations are creating awareness among people will also support the growth of metastatic bone disease market. However, the high cost of research and development and long duration of product development may hamper the growth of the metastatic bone disease.
Based on treatment type, the metastatic bone disease market is segmented into medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication segment is expected to grow significantly due to the primary preference for the medication for treatment. Based on origin, the metastatic bone disease market is segmented into breast, lung, thyroid, kidney, prostate, and others. Breast cancer segment is expected to dominate the metastatic bone disease market. Based on the end user, the metastatic bone disease market is segmented into hospitals, ambulatory surgical centers, and specialty clinics. Hospital segment is expected to dominate the metastatic bone disease market over the forecast period.
In terms of region, the global metastatic bone disease market is classified into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. North America is expected to be the largest market for metastatic bone disease market which is further followed by Europe during the forecast period. This growth is supported by an increase in healthcare facilities and an increase in research and development which is further supported by FDA approval of the various new drugs launched in the market. The Asia Pacific is expected to experience a significant growth due to the increased prevalence and awareness among people. Latin America and the Middle East and Africa are expected to experience a moderate growth over the forecast period.
Some of the key players in metastatic bone disease market include Merck & Co., Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Amgen, Inc., Novartis AG, Bayer AG, BTG Plc, Fresenius Kabi AG, Medtronic, Boston Scientific Corporation, and others.
Request the coronavirus impact analysis across industries and markets